Pharmaceutical major Lupin Ltd has announced that its biosimilar Ranibizumab has been launched across Europe, excluding Germany, by its commercial partner Sandoz.
The market entry follows the European Commission's formal approval of Ranluspec in both vial and pre-filled syringe presentations. According to the company, this rollout represents a key step in expanding patient access to biologic treatment options for specific retinal conditions.
Ranibizumab is medically indicated for the treatment of several eye conditions, including neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, proliferative diabetic retinopathy, and choroidal neovascularization.
Explaining the mechanism of the drug, Lupin noted that Ranibizumab functions as a recombinant humanised IgG1 monoclonal antibody fragment designed to bind and inhibit vascular endothelial growth factor A.
Commenting on the development, Thierry Volle, Lupin President EMEA and Emerging Markets, stated that the commercial availability of Ranluspec in Europe through Sandoz broadens access to the biosimilar for patients dealing with retinal and choroidal vascular diseases.
"The commercialization of pharmaceutical products in highly regulated markets like Europe requires strong distribution partnerships. Lupin's collaboration with Sandoz for the rollout of Ranluspec demonstrates how established Indian pharmaceutical companies leverage global networks to scale their biosimilar portfolios. This market expansion highlights the strategic importance of regulatory approvals and international partnerships in the healthcare sector." — Dr. Shishir Gupta, Founder & CEO, StartupLanes
Recent StartupLanes Articles
Browse through our 30 latest publications on venture capital, startups, and angel investing.